Regeneron and Sanofi's Dupixent Gains European Approval for Uncontrolled COPD
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi have received European Commission approval for Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD. This is the first global approval for Dupixent in COPD, with additional submissions under review in the U.S., China, and Japan.
July 03, 2024 | 7:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received European Commission approval for Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD. This approval marks the first global regulatory nod for Dupixent in COPD, potentially expanding its market and revenue.
The European approval of Dupixent for COPD is a significant milestone for Regeneron, potentially leading to increased market share and revenue. The news is highly relevant and important for investors as it marks the first global approval, with more submissions under review.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100